By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Oncology is now available. According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "This multicenter phase II trial investigated cetuximab combined with chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC). Eligible patients with non-resectable, locally-advanced ESCC received cetuximab 400 mg/m(2) loading dose on day 1; and on day 1 of the 2nd-7th weeks: cetuximab 250 mg/m(2), paclitaxel 45 mg/m(2), and cisplatin 20 mg/m(2), concurrent with 59.4 Gy/33 fractions of radiation therapy."
Our news editors obtained a quote from the research from the University of Texas, "Primary endpoint was clinical response rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and KRAS status. Of 55 patients enrolled, 45 completed therapy. Forty-four patients had a clinical response: 29 complete response and 15 partial response. One-year PFS and OS of 45 evaluable patients were 84.23% and 93.33%, respectively, and 2-year PFS and OS were 74.87% and 80.00%, respectively. Non-hematologic adverse events were generally grade 1 or 2; primarily rash (92.7%), mucositis (45.5%), fatigue (41.8%), and nausea (38.2%). Grade 3 hematologic adverse events included neutropenia (32.7%) and anemia (1.8%). No KRAS mutations were identified in 50 evaluated samples."
According to the news editors, the research concluded: "Cetuximab can be safely administered with chemoradiotherapy to patients with locally-advanced ESCC and may improve clinical response rate."
For more information on this research see: Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail. Radiotherapy and Oncology, 2013;109(2):275-280. Radiotherapy and Oncology can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Radiotherapy and Oncology - www.elsevier.com/wps/product/cws_home/506042)
The news editors report that additional information may be obtained by contacting X. Meng, Univ Texas Houston, MD Anderson Canc Center, Houston, TX 77030, United States. Additional authors for this research include J.H. Wang, X.D. Sun, L.H. Wang, M. Ye, P.B. Feng, G.Y. Zhu, Y. Lu, C. Han, S.C. Zhu, Z.X. Liao and J.M. Yu (see also Oncology).
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Biotechnology, Pharmaceuticals, Texas, Houston, Genetics, Oncology, Cetuximab, United States, EGFR Inhibitors, Radiation Therapy, Adverse Drug Reaction, Squamous Cell Carcinoma, North and Central America, Tyrosine Kinase Inhibitors, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC